BEXSERO
Multicomponent Meningococcal B Vaccine
(recombinant, adsorbed)

Multicomponent Meningococcal B Vaccine
(recombinant, adsorbed)
The hyper-endemic serogroup B strain ST-269 emerged in the province of Quebec in 2003 and attributed to a steadily increasing incidence of serogroup B IMD with the Saguenay-Lac-Saint-Jean (SLSJ) region having the greatest incidence rates in Quebec.
A short-term mass immunization campaign was initiated in May 2014 with BEXSERO, targeting individuals between 2 months to 20 years of age residing or attending school in SLSJ.
The disease incidence in SLSJ from 2014 to 2018 decreased in the targeted age group.
In the UK, a national immunization program with BEXSERO was initiated in September 2015 using a two-dose schedule in infants (at 2 and 4 months of age) followed by a booster (at 12 months of age). Public Health England conducted a 3-year observational study at the national level covering the entire birth cohort from September 2015 to August 2018.
See the full study, published in 2020 in the New England Journal of Medicine
This page is for Healthcare Professionals only. If you are not a Healthcare Professional, please visit Bexsero.ca.